Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

NCT01780506 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

872

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV
HIV Infections

Interventions

DRUG: E/C/F/TAF
DRUG: E/C/F/TDF
DRUG: E/C/F/TDF Placebo
DRUG: E/C/F/TAF Placebo

Sponsor

Gilead Sciences